Back to News
Market Impact: 0.3
Pharming Q3 Revenue Jumps 21%, CVID Data Due In November
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Pharming Group reported double-digit revenue growth and higher profitability in Q3 2026, attributing the gains to continued demand for its rare disease therapies RUCONEST and Joenja. The article provides no specific revenue or profit figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
PHAR0.65
More News
- Pharming Q3 operating profit jumps 89%, narrows 2026 revenue outlook
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI